logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hypertensive Disease

    FiltersReset Filters
    17 results

    • atacand

      (Candesartan Cilexetil)
      ANI Pharmaceuticals, Inc.
      Usage: ATACAND is indicated for treating hypertension in adults and children aged 1-17, reducing cardiovascular event risks. It is also indicated for heart failure in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to decrease cardiovascular deaths and hospitalizations.

    • atacand hct

      (Candesartan Cilexetil and Hydrochlorothiazide)
      ANI Pharmaceuticals, Inc.
      Usage: ATACAND HCT is indicated for treating hypertension to lower blood pressure, thereby reducing the risk of cardiovascular events like strokes and myocardial infarctions. It is not meant for initial therapy and should be part of a broader cardiovascular risk management strategy.

    • cardizem la

      (Diltiazem Hydrochloride)
      Bausch Health US LLC
      Usage: CARTIZEM LA is indicated for treating hypertension to lower blood pressure, reducing cardiovascular event risks, including strokes and heart attacks. Additionally, it improves exercise tolerance in patients with chronic stable angina. It can be used alone or in combination with other antihypertensive medications.

    • diltiazem hydrochloride

      (Diltiazem Hydrochloride)
      Slate Run Pharmaceuticals, LLC
      Usage: Diltiazem Hydrochloride Extended-Release Capsules are indicated for treating hypertension, either alone or with other antihypertensives, and for managing chronic stable angina.

    • diovan

      (valsartan)
      Novartis Pharmaceuticals Corporation
      Usage: Diovan is indicated for treating hypertension in adults and pediatric patients aged one and older, reducing cardiovascular risks. It also reduces hospitalization risk in adults with heart failure (NYHA class II-IV) and lowers cardiovascular mortality risk in stable patients with left ventricular dysfunction post-myocardial infarction.

    • edarbi

      (Azilsartan kamedoxomil)
      Azurity Pharmaceuticals, Inc.
      Usage: Edarbi is indicated for treating hypertension in adults to lower blood pressure, thereby reducing the risk of cardiovascular events such as strokes and myocardial infarctions. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.

    • edarbyclor

      (Azilsartan kamedoxomil and chlorthalidone)
      Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
      Usage: Edarbyclor is indicated for treating hypertension to lower blood pressure, particularly in patients not adequately controlled on monotherapy. It may also serve as initial therapy for those needing multiple drugs to reach blood pressure goals, reducing the risk of cardiovascular events like strokes and heart attacks.

    • inderal

      (propranolol hydrochloride)
      ANI Pharmaceuticals, Inc.
      Usage: Inderal LA is indicated for managing hypertension (alone or with other agents), reducing angina frequency, prophylaxis of migraine headaches, and improving symptoms in patients with hypertrophic subaortic stenosis. It is not recommended for hypertensive emergencies or for treating acute migraine attacks.

    • inspra

      (eplerenone)
      Viatris Specialty LLC
      Usage: INSPRA is indicated for improving survival in stable patients with symptomatic heart failure and reduced ejection fraction post-myocardial infarction, as well as for treating hypertension to lower blood pressure and reduce cardiovascular event risks, including strokes and myocardial infarctions. It can be used alone or with other antihypertensives.

    • inzirqo

      (hydrochlorothiazide)
      ANI Pharmaceuticals, Inc.
      Usage: INZIRQO is indicated for treating hypertension in adults and pediatric patients to lower blood pressure, thereby reducing the risk of cardiovascular events. It is also used to manage edema linked to congestive heart failure, hepatic cirrhosis, and renal disease, including nephrotic syndrome.